Short C8 Chromatography Column for Phospholipid Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in performing LC-MS assays of immunosuppressant drugs in whole blood using electrospray ionization is ion suppression caused by co-eluting phospholipids, which are not adequately separated from the analytes due to their similar hydrophobic characteristics, leading to reduced analyte ionization efficiency and inaccurate quantitation.
Innovation Solution
Utilizing a short reverse-phase chromatographic column (30 mm or less) with a C8 stationary phase and a mobile phase composition that varies from 30% MPA to 100% MPB, along with a TurboFlow column for initial cleanup, effectively separates phospholipids from immunosuppressant drugs, reducing ion suppression and allowing for reliable quantitation using heated electrospray ionization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a conventional length reverse-phase chromatographic column is used to separate phospholipids from immunosuppressant drugs, then phospholipid removal is improved, but analysis time and phospholipid carryover between samples increase
Solution Approach 1:
The patent changes the physical parameter of column length from conventional (50-150 mm) to short (30 mm or less), which fundamentally alters the separation mechanism. The short column relies on optimized mobile phase composition and flow rate parameters to achieve rapid phospholipid-phospholipid separation without the time penalty of longer columns, resolving the contradiction between separation quality and analysis speed.
Solution Approach 2:
The patent employs dynamic optimization of mobile phase composition (gradual increase of organic solvent from 30% to 100% over the run) and flow rate adjustments to maximize phospholipid elution speed. This dynamic approach allows the short column to achieve in minutes what would require static, prolonged exposure in conventional columns, eliminating the time-loss contradiction.
2Reliability
If a long reverse-phase chromatographic column is used to reduce phospholipid carryover, then carryover between samples is reduced, but column phospholipid accumulation and analysis time increase
Solution Approach 1:
The patent changes the column length parameter to 30 mm or less, which prevents phospholipid accumulation by limiting the stationary phase volume where phospholipids can adsorb. Combined with optimized mobile phase strength, this parameter change ensures phospholipids elute rapidly without accumulating, maintaining reliability while avoiding the time and accumulation problems of long columns.
Solution Approach 2:
The patent incorporates a preliminary high-strength wash step (100% organic solvent) between sample injections that proactively removes phospholipids before they can accumulate. This preliminary action on the short column prevents carryover without requiring the extended column length that would otherwise be needed, resolving the contradiction between reliability and accumulation.
3Measurement precision
If phospholipids are not adequately separated from immunosuppressant drugs, then ion suppression occurs, but quantitation accuracy decreases
Solution Approach 1:
The patent extracts phospholipids from the sample matrix before chromatographic analysis through selective precipitation with cold acetonitrile. This preliminary extraction removes the harmful phospholipid component that causes ion suppression, allowing accurate quantitation of immunosuppressant drugs without the interference that would otherwise require extensive chromatographic separation.
Solution Approach 2:
The patent segments the analysis into two distinct stages: (1) phospholipid removal via selective precipitation, and (2) immunosuppressant drug quantitation via chromatography-mass spectrometry. This segmentation isolates the ion suppression problem to a removable fraction, ensuring accurate quantitation without requiring perfect chromatographic separation of phospholipids from analytes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate and reproducible quantitation of immunosuppressant drugs like everolimus, sirolimus, and cyclosporin A by minimizing phospholipid interference, improving sensitivity and reducing carryover effects, thus maintaining analysis accuracy at low concentration levels.
Implementation Method 1
passing the sample dissolved in a mobile phase through a length of 30 mm or less of a stationary phase of a reversed-phase chromatographic column so as to separate the analytes from one another
Implementation Method 2
phospholipids are so strongly partitioned onto the stationary phase of reverse-phase analytical columns
Implementation Method 3
ionizing molecules of the eluted separated analytes by a heated electrospray ionization source of a mass spectrometer so as to generate a plurality of precursor ion species
Implementation Method 4
heated electrospray ionization
Implementation Method 5
Mass spectrometry (MS) is an analytical technique to filter, detect, identify and/or measure compounds by the mass-to-charge ratios of ions formed from the compounds
Data Source
AI summary
A method for assaying one or more immunosuppressant drug analytes in a sample derived from whole blood comprises: (a) passing the sample dissolved in a mobile phase through a length of 30 mm or less of a stationary phase of a reversed-phase chromatographic column; (b) eluting the separated analytes from the reversed-phase chromatographic column; (c) ionizing molecules of the eluted separated analytes by a heated electrospray ionization source of a mass spectrometer so as to generate a plurality of precursor ion species; (d) isolating, for each analyte, a respective one of the precursor ion species; (e) fragmenting ions of each of the isolated precursor ion species in a fragmentation cell of the mass spectrometer so as to generate a plurality of product ions therefrom; and (f) detecting, for each analyte, the presence and quantity of a respective one of the product ion species using a detector of the mass spectrometer.